Tumour heterogeneity — clonal evolution of cancer limits effectiveness of targeted systemic therapies

Tumour heterogeneity — clonal evolution of cancer limits effectiveness of targeted systemic therapies

User Photo
AudioMedica

6 years
2,892 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
SAN FRANCISCOThe ability of cancer cells to evolve clonally into molecularly distinct strands needs to be considered when selecting targeted therapies to treat renal cancer, according to Dr Tom Powles MBBS, MRCP, MD speaking at the ASCO GU Cancers Symposium here. Dr Tomasz Beer, MD FACP from Oregon Health & Science University in Portland acknowledged that heterogeneity was also a barrier to prostate cancer treatment but he felt it would be overcome in this and other genitourinary cancers by using combination targeted therapies just as HIV-AIDS was being beaten by multi-drug approaches.

CONTACT:
Dr. Tom Powles MBBS, MRCP, MD
Barts Cancer Institute, London, UK SOURCE:

SOURCE:
General Session: Clinical and genetic heterogeneity in renal cell carcinoma

LINK: http://gucasym.org/2014-meeting-program#Saturday
Up Next Autoplay
>